Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: Results of a randomized phase III trial

Haematologica

Volumn 98, Issue 5, 2013, Pages 784-788

  Dimopoulos, Meletios A ^a   Delforge, Michel ^b   Hájek, Roman ^c,d   Kropff, Martin ^e   Petrucci, Maria T ^f   Lewis, Philip ^g   Nixon, Annabel ^h   Zhang, Jingshan ⁱ   Mei, Jay ⁱ   Palumbo, Antonio ^j  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c University of Ostrava School of Medicine ^*

^d UNIVERSITY OF OSTRAVA   (Czech Republic)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g Celgene GmbH   (Germany)

^h ICON PLC   (United Kingdom)

ⁱ CELGENE CORPORATION   (United States)

^j UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

AGED; ARTICLE; COGNITION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DYSPNEA; FATIGUE; HUMAN; INDUCTION CHEMOTHERAPY; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PAIN; PHASE 3 CLINICAL TRIAL; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MAINTENANCE CHEMOTHERAPY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MELPHALAN; MULTIPLE MYELOMA; PREDNISONE; QUALITY OF LIFE; QUESTIONNAIRES; THALIDOMIDE;

EID: 84877072648     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.074534     Document Type: Article

References (24)

1. Kamphuis M, Ottenkamp J, Vliegen HW, Vogels T, Zwinderman KH, Kamphuis RP, et al. Health related quality of life and health status in adult survivors with previously operated complex congenital heart disease. Heart. 2002;87(4):356-362.
2. Centers for Disease Control and Prevention. Measuring healthy days: Population assessment of health-related quality of life. Centers for Disease Control and Prevention. 2000. Atlanta, GA, USA.
3. Buijs C, de Vries EG, Mourits MJ, Willemse PH. The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat Rev. 2008;34(7):640-655.
4. Harris K, Chow E, Zhang L, Velikova G, Bezjak A, Wu J, et al. EORTC Quality of Life Group. Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. Eur J Cancer. 2009;45(14):2510-2518.
5. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009;7:102.
6. Arden-Close E, Pacey A, Eiser C. Healthrelated quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk Lymphoma. 2010;51(4):628-640.
7. Osoba D. Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol. 2011;3(2):57-71.
8. Wisløff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1997;97(1):29-37.
9. Lee SJ. Patient-reported outcomes in multiple myeloma. J Natl Compr Canc Netw. 2004;2(4):379-383.
10. Kvam AK, Fayers P, Wisloff F. What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. Eur J Haematol. 2010;84(4):345-353.
11. Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Cancer. 1999; 35(11):1565-1570.
12. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
13. Palumbo A, Adam Z, Kropff M, Foà R, Catalano J, Gisslinger H, et al. A phase 3 study evaluating the efficacy and safety of lenalidomide (len) combined with melphalan and prednisone followed by continuous lenalidomide maintenance (MPR-R) in patients (pts) ≥ 65 years (yrs) with newly diagnosed multiple myeloma (NDMM): updated results for pts aged 65-75 yrs enrolled in MM-015. Blood (ASH Annual Meeting Abstracts). 2011;118(21):(Abstract 475).
14. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a qualityof- life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376.
15. Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E, et al. An international field study of the reliability and validity of a disease- specific questionnaire module (the QLQ-MY20) in assessing quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43(11):1670-1678.
16. EORTC Quality of Life questionnaires. Available from: http://groups.eortc.be/qol/. Accessed April 2013.
17. EORTC QLQ-C30 Scoring Manual. EORTC, Brussels. 3rd ed., 2001. Available from: http://groups.eortc.be/qol/manuals. Accessed April 2013.
18. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407-415.
19. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality-of-Life Questionnaire. J Clin Epidemiol. 1994;47(1):81-87.
20. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intraindividual changes in health-related qualityof- life. J Clin Epidemiol. 1999;52(9):861-873.
21. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality-of-life. Med Care. 1999;37(5):469-478.
22. Dimopoulos MA, Delforge M, Hajek R, Kropff M, Petrucci MT, Lewis P, et al. Lenalidomide plus melphalan and prednisone followed by lenalidomide maintenance provides favourable efficacy and health-related quality of life in newly diagnosed mutiple myeloma patients ≥65 years. Haematologica. 2011;96(s2):365-366.
23. Cocks K, King MT, Velikova G, Martyn St- James M, Fayers PM, Brown JM. Evidencebased guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011; 29(1):89-96.
24. Delforge M, Dhawan R, Robinson D Jr, Meunier J, Regnault A, Esseltine DL, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012; 89(1):16-27.